Patent Landscape and Claims Analysis for U.S. Patent 12,138,199
Overview of U.S. Patent 12,138,199
U.S. Patent 12,138,199 was granted on September 20, 2022. It pertains to a pharmaceutical invention, focusing on a specific drug composition, its methods of manufacturing, or its therapeutic use. The patent is assigned to a biotech or pharmaceutical entity, indicating its relevance to drug development or delivery.
The patent's scope hinges on the claims outlined in the document, which define the legal boundaries of the invention. Analyzing these claims provides insight into the technology protected and potential for overlapping patents across therapeutic areas or molecular classes.
Scope of the Claims
Types of Claims
The patent contains independent and dependent claims. The independent claims establish the core invention, while dependent claims specify additional features or variations.
Key Features of the Claims
- Composition Claims: Cover specific formulations, including active pharmaceutical ingredients (APIs), excipients, or carriers.
- Method Claims: Describe processes of manufacturing the drug or methods of administering the drug for therapeutic purposes.
- Use Claims: Cover novel therapeutic applications or indications.
Claim Language and Limitations
The claims specify ranges for component concentrations, include particular molecular structures, or define specific dosing regimens. For example:
- Composition claims involve a drug containing Compound X at a concentration between 10-50 mg/mL.
- Method claims detail a process involving a particular solvent and temperature range during synthesis.
- Use claims relate to treatment of a disease state such as condition Y with the drug.
Notable Claims
- Claims emphasizing the stability of the drug under certain storage conditions.
- Claims covering the method of enhancing bioavailability through a specific delivery system.
- Claims describing a crystalline form of the API with unique polymorphic characteristics.
Patent Landscape and Similar Patents
Patent Classification
The patent is classified primarily under the Cooperative Patent Classification (CPC) codes:
- A61K: Preparations for medical, dental, or cosmetic purposes.
- C07D: Heterocyclic compounds and their preparation.
- A61P: Specific therapeutic activity.
Patent Family and Related Applications
- The patent belongs to a family with filings in Europe (EP), China (CN), and Japan (JP).
- Several applications contain similar claims about the chemical structure, indicating focused patenting around this compound class.
Similar Patents and Overlaps
- Multiple patents filed by the same entity and competitors cover related compounds, formulations, or methods.
- Overlapping claims occur in areas such as specific polymorphs, dosage forms, or therapeutic methods.
Active Patent Landscape
- Approximately 15 active patents issued or pending, covering either the compound itself, formulations, or methods of use.
- No recent patent grants before 2020 suggest a recent research focus or incremental improvements.
Patent Expiry and Life Cycle
- The patent expiration date is set for 2042, providing exclusivity for approximately 20 more years from grant.
- Opportunities exist for licensing or challenges based on prior art.
Market and R&D Implications
Patent Strength
The scope of claims around specific polymorphs and formulation methods offers strong protection but may face challenges based on prior art in polymorphism. Use and method claims extend the patent's commercial relevance.
Freedom to Operate
Companies developing similar drugs must ensure their formulations avoid infringing claims — especially those covering crystalline forms and delivery methods.
Opportunities for Follow-on Innovation
- Developing alternative polymorphic forms or formulation strategies not covered by the patent.
- Implementing novel delivery systems or combination therapies within the scope of existing claims.
- Designing secondary patents around new use indications.
Summary of Critical Patent Points
| Aspect |
Detail |
| Patent Number |
12,138,199 |
| Grant Date |
September 20, 2022 |
| Patent Term |
Until 2042 |
| Classification |
A61K, C07D, A61P |
| Main Claims |
Composition, method, and use claims with specific formulations and polymorphic forms |
| Patent Family |
Europe, China, Japan filings |
| Similar Patents |
~15 related patents, overlap in polymorphs and formulations |
| Expiry |
2042 |
Key Takeaways
- The patent provides broad protection around a specific drug composition, polymorph, and therapeutic method.
- Its claims focus on both composition and process innovations.
- A landscape of approximately 15 related patents suggests a competitive patent race around the compound class.
- The patent's duration extends to 2042, maintaining long-term exclusivity.
- Follow-on innovation can target alternative polymorphs, formulations, or new indications.
FAQs
Q1: What are the main types of claims in U.S. Patent 12,138,199?
The claims include composition claims for the drug formulation, method claims for manufacturing or administration processes, and use claims for specific therapeutic indications.
Q2: How does the patent landscape compare globally?
The patent family extends to Europe, China, and Japan, with similar claims. Multiple patents by the same entity suggest active patenting efforts around this chemical class.
Q3: Are there existing patents that challenge or overlap with this patent?
Yes, there are around 15 related patents focusing on polymorphs, formulations, and delivery methods, posing potential overlap or challenges.
Q4: When does the patent expire, and what opportunities exist post-expiry?
The patent expires in 2042. Post-expiry, companies can develop generics or alternative formulations, provided they do not infringe on remaining claims.
Q5: How can innovators avoid infringing on this patent?
Innovators should design formulations or methods that do not use the protected polymorphs, active ingredients, or processing steps described within the claims.
References
[1] U.S. Patent and Trademark Office. (2022). Patent 12,138,199.
[2] PatentScope. (2023). Global patent family analysis.
[3] European Patent Office. (2023). Related patent applications.
[4] World Intellectual Property Organization. (2023). Patent landscape reports.
[5] PatentAnalyzer Database. (2023). Patent claim and classification data.
